Bioretec Ltd – Managers’ transactions – Alan Donze

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Alan Donze

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.15 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Alan Donze

Position: Chief Executive Officer

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103643/7/6

____________________________________________

Transaction date: 2025-04-08

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd, Option program 2025-2

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 610105 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 610105 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd – Managers’ transactions – Justin Barad

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Justin Barad

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.00 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Justin Barad

Position: Member of the Board/Deputy member

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103639/6/6

____________________________________________

Transaction date: 2025-04-08

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd, Option program 2025-1

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 25000 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd – Managers’ transactions – Antti Vasara

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Antti Vasara

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.00 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Antti Vasara

Position: Member of the Board

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103634/7/6

____________________________________________

Transaction date: 2025-04-07

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd,  Option program 2025-1 

Nature of transaction: ACCEPTANCE OF A STOCK OPTION 

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 25000 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd – Managers’ transactions – Päivi Malinen

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Päivi Malinen

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.00 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Päivi Malinen

Position: Member of the Board/Deputy member

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103640/7/6

____________________________________________

Transaction date: 2025-04-08

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd, Option program 2025-1

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 25000 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd – Managers’ transactions – Michael Piccirillo

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Michael Piccirillo

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.00 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Michael Piccirillo

Position: Member of the Board/Deputy member

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103630/9/8

____________________________________________

Transaction date: 2025-04-07

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd, Option program 2025-1

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 25000 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd – Managers’ transactions – Kustaa Poutiainen

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Kustaa Poutiainen

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.00 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Kustaa Poutiainen

Position: Member of the Board/Deputy member

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103636/6/6

____________________________________________

Transaction date: 2025-04-08

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd, Option program 2025-1

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 25000 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd – Managers’ transactions – Sarah van Hellenberg Hubar-Fisher

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd – Managers’ transactions – Sarah van Hellenberg Hubar-Fisher

Bioretec Ltd      Managers’ transactions 9 April 2025 at 17.00 p.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Sarah van Hellenberg Hubar-Fisher

Position: Member of the Board/Deputy member

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 103679/5/4

____________________________________________

Transaction date: 2025-04-09

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: Bioretec Ltd, Option program 2025-1

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

 

Transaction details

(1): Volume: 25000 Unit price: 0 EUR

 

Aggregated transactions (1):

Volume: 25000 Volume weighted average price: 0 EUR

Further enquiries

Johanna Salko, CFO, tel. +358 40 754 8172

 

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

 

by Admin

Bioretec Ltd's Board of Directors has decided on a new option program for the CEO

<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd's Board of Directors has decided on a new option program for the CEO

Bioretec Ltd Company announcement 21st of March 2025 at 3:00 p.m. EET

The Board of Directors of Bioretec Ltd has on 21st of March 2025 resolved, on the basis of the authorization granted by the company's Annual General Meeting on 21st of March 2025, to establish a new option program as an incentive scheme for Alan Donze, the CEO of the company (the “CEO”).

There is a weighty financial reason for issuing option rights, as the option program is part of the incentive and commitment program of the CEO.

The Board of Directors has resolved to issue 610,105 option rights to the CEO. Each of the option rights entitle to the subscription of one (1) share in the company.

The option rights are issued free of charge.  Shares can be subscribed to on the basis of the option rights, as follows:

  • One third of the option rights given to the option right holder: The share subscription period begins on the 20th of May 2025;
  • The remaining two thirds of the option rights given to the option right holder: The share subscription period begins monthly in installments of 1/24th per month on the 20th day of each month in such a way that the share subscription period for the first 1/24th installment shall begin on the 20th of June 2025.

The subscription period for the shares to be subscribed based on the option rights shall end on 31 December 2030.

The subscription price for a share subscribed for with one option right is EUR 2.79, which is the trade volume weighted average quotation of the share on Nasdaq Helsinki Ltd maintained Nasdaq First North Growth Market Finland marketplace from 20 December 2024 to 20 March 2025 increased by 10%, rounded downwards to nearest cent.

The subscription price payable for shares shall be recorded in the company's reserve for invested unrestricted equity. The amount of dividends and distribution of assets per share paid will be deducted from the share subscription price.

As a result of the subscription of shares based on the option rights, the number of shares in the company can increase by a maximum of 610,105 shares. The shares to be subscribed based on the option rights to be issued correspond to a maximum of 2.48 percent of all the company's shares and votes on the date of the resolution after the potential share subscription.

The theoretical market value of one option right is approximately EUR 1.1357 and the theoretical market value of all option rights combined is approximately EUR 692,896. The theoretical market value of an option right has been calculated using the Black & Scholes stock option pricing model with the following input factors: valuation date 20 March 2025, share price EUR 2.33, share subscription price EUR 2.79, risk free interest rate 2.51 %, time to maturity of option rights 5.79 years and volatility 55.65 %.

The terms and conditions of the option program are attached to this announcement.

Further enquiries

Kustaa Poutiainen, Chairperson of the Board, + 358 40 042 4506

 

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

 

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

by Admin

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

<br /> ViewReleaseInStandardHtml<br />

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

Bioretec Ltd  Company announcement 21 March 2025 at 2:30 p.m. EET

The Annual General Meeting of Bioretec Ltd was held on 21 March 2025 in Tampere, Finland.

 

The Annual General Meeting approved the financial statements for the financial year 1 January–31 December 2024 and resolved to discharge the members of the Board of Directors and the CEO from liability for the financial period 1 January–31 December 2024.

 

The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that the loss of EUR 4,669,883.08 for the financial period 1 January–31 December 2024 will be credited in the equity as Profit/loss for previous financial periods and that no dividend shall be distributed.

 

Number of members of the Board of Directors, election of members of the Board and their remuneration

 

The Annual General Meeting resolved that the number of members of the Board of Directors will be six (6). Michael Piccirillo, Sarah van Hellenberg Hubar-Fisher, Päivi Malinen and Kustaa Poutiainen were re-elected as members of the Board. Antti Vasara and Justin Barad were elected as new members of the Board of Directors. The term of the Board of Directors will end at the conclusion of the Annual General Meeting 2026.

 

The Annual General Meeting resolved that the Chairperson of the Board will be paid EUR 3,750 per month and the Deputy Chairperson EUR 2,500 per month. Members of the Board will be paid EUR 2,000 per month.

 

Reasonable travel expenses of the members of the Board of Directors will be reimbursed in accordance with the maximum amount of the respective travel allowance base approved by the Tax Administration.

 

Election and remuneration of auditor

 

The Annual General Meeting elected audit firm PricewaterhouseCoopers Oy as the auditor of the company until the closing of the 2026 Annual General Meeting. Audit firm PricewaterhouseCoopers Oy has notified the company that it will appoint Kalle Laaksonen, Authorized Public Accountant, as the responsible auditor. The auditor will be compensated as reasonably invoiced.

 

Authorization of the Board of Directors to resolve on the issuance of shares and special rights entitling to shares

 

The Annual General Meeting authorized the Board of Directors to resolve on the issuance of shares, as well as the issuance of option rights and other special rights entitling to shares pursuant to Chapter 10 of the Finnish Companies Act, as follows:

 

Pursuant to the authorization, up to 7,000,000 shares (including shares to be issued based on the special rights) may be issued, which on the date of the notice to the Annual General Meeting corresponded to approximately30% of all the shares in the company.

 

Shares or special rights entitling to shares may be issued in one or more tranches, either with or without payment. The shares issued pursuant to the authorization may be new shares or shares in the company's possession.

 

The authorization may be used for financing or execution of acquisitions or other business arrangements, to strengthen the balance sheet and financial position of the company, or for other purposes determined by the Board of Directors. The authorization may not be used for share-based incentive or commitment plans.

 

Pursuant to the authorization, the Board of Directors may resolve upon issuing new shares, without consideration, to the company itself.

 

The Board of Directors is authorized to resolve on all terms for share issues and granting of special rights entitling to shares in the company. The Board of Directors is authorized to resolve on a share issue and an issue of special rights entitling to shares according to the shareholders’ pre-emptive rights and/or in deviation from the shareholders' pre-emptive right, provided that there is a weighty financial reason for the company to do so.

 

The authorization is valid until the end of the next Annual General Meeting, however no longer than until 30th of June 2026. The authorization cancels previous unused share issue authorizations.

 

 

Resolution on the issue of option rights to the members of the Board of Directors (Option Program 2025-1)

 

The Annual General Meeting resolved on an option program directed at the members of the Board of Directors and on the issue of option rights. There are weighty financial reasons for the company to issue the option rights because the option rights are intended to be a part of the incentive and commitment program of the members of the Board of Directors

 

The Annual General Meeting resolved to issue 25,000 option rights to each member elected at the Annual General Meeting, i.e. an aggregate of 150,000 option rights. Each option right entitles to subscribe for one (1) new share. The option rights are issued free of charge.

 

Shares can be subscribed to on the basis of the option rights, as follows:

  • with the first 33% of the option rights given to the option right holder:

the share subscription period starts on the 22nd of March 2026,

  • the following 33% of the option rights given to the option right holder:

the share subscription period starts on the 22nd of March 2027,

  • the remaining 34% of the option rights given to the option right

holder: the share subscription period starts on the 22nd of March 2028.

 

The subscription period for the shares ends on the 31st of December 2030.

 

The subscription price for a share subscribed for with one option right is EUR 2.79. The subscription price is the trade volume weighted average quotation of the share on Nasdaq Helsinki Ltd maintained Nasdaq First North Growth Market Finland marketplace from 20 December 2024 to 20 March 2025 increased by 10%, rounded downwards to the nearest cent.

 

The subscription price payable for shares shall be recorded in the company's reserve for invested unrestricted equity. The amount of dividends and distribution of assets per share paid will be deducted from the share subscription price.

 

As a result of the subscription of shares based on the option rights, the number of shares in the company can increase by a maximum of 150,000 shares. The shares to be subscribed based on the option rights to be issued correspond to a maximum of 0.61 percent of all the company's shares and votes on the date of the resolution (0.64 percent at the date of the notice to the General Meeting), after the potential share subscription.

 

The theoretical market value of one option right is approximately EUR 1.1357 and the theoretical market value of all option rights combined is approximately EUR 170,340. The theoretical market value of an option right has been calculated using the Black & Scholes stock option pricing model with the following input factors: valuation date 20 March 2025, share price EUR 2.33, share subscription price EUR 2.79, risk free interest rate 2.51 %, time to maturity of option rights 5.79 years and volatility 55.65 %.

 

The terms and conditions of the option program are available on the webpage of the company.

 

 

Authorization of the Board of Directors to resolve on the issuance of option rights to the CEO of the company (Option Program 2025-2)

 

The Annual General Meeting resolved to authorize the Board of Directors to resolve on the issuance of option rights as follows:

 

  • The option rights can be granted to Alan Donze, the CEO of the company (the “CEO”);
  • Based on the option rights issued under the authorization, a maximum of 610,105 shares can be subscribed, which corresponded to approximately 2.6% of all the company’s shares on the date of the notice of the General Meeting.
  • Option rights can be issued in one or more tranches.
  • The subscription price of the shares subscribed with option rights shall be determined based on the trade volume weighted average quotation of the share on Nasdaq Helsinki Ltd maintained Nasdaq First North Growth Market Finland marketplace from 20 December 2024 to 20 March 2025 increased by 10%, rounded downwards to nearest cent.
  • The Board of Directors decides on all other terms and conditions related to the issuance of stock options.
  • The authorization is valid until the end of the next Annual General Meeting, however no longer than until 30 June 2026.

 

 

Authorization of the Board of Directors to resolve on the issuance of option rights (Option Program 2025-3)

 

 

The Annual General Meeting resolved to authorize the Board of Directors to resolve on the issuance of option rights as follows:

 

  • The authorization can be used to issue option rights to the employees of the company and its subsidiaries as well as to members of the company’s Key Opinion Leader group and consultants (“Target Group”). The authorization cannot be used to issue option rights to the CEO or members of the Board of Directors of the company.
  • Based on the option rights issued under the authorization, a maximum of 1,127,000 shares can be subscribed, which corresponded to approximately 4.8% of all the company’s shares on the date of the notice of the General Meeting.
  • Option rights can be issued in one or more tranches.
  • The subscription price of the shares subscribed with option rights shall be determined based on the trade volume weighted average quotation of the share on Nasdaq Helsinki Ltd maintained Nasdaq First North Growth Market Finland marketplace from 20 December 2024 to 20 March 2025 increased by 10%, rounded downwards to nearest cent.
  • The Board of Directors decides on all other terms and conditions related to the issuance of the option rights.
  • The authorization is valid until 31 December 2026.

 

 

Amendment of the Articles of Association

 

The Annual General Meeting resolved to amend Article 10 of the Articles of Association to include the possibility of holding a General Meeting as a so-called remote meeting. Before the proposed amendment, Article 10 of the Articles of Association has been empty.

 

The Annual General Meeting resolved to amend Article 10 to read as follows:

 

10 § Organization of the General Meeting as a hybrid or remote meeting

 

The Board of Directors may decide that a shareholder may also participate in the General Meeting by fully exercising their right to vote during the meeting by means of a telecommunication connection and a technical aid (hybrid meeting).

 

The Board of Directors may also decide that the General Meeting shall be held without a meeting place in such a way that the shareholders exercise their voting rights fully and in a timely manner during the meeting by means of a telecommunication connection and a technical aid (remote meeting).

 

The amendment of the Articles of Association will take effect upon registration in the Finnish Trade Register.

 

Minutes of the Annual General Meeting

 

The minutes of the Annual General Meeting will be available no later than 4th of April 2025 on the company's website at https://investors.bioretec.com/en/corporate_governance/annual_general_meeting_2025. 

 

Resolutions of the constitutive meeting of the Board of Directors

 

At its constitutive meeting held after the Annual General Meeting, the Board of Directors of Bioretec Ltd elected Kustaa Poutiainen as the Chairperson of the Board and Sarah van Hellenberg Hubar-Fisher as the Deputy Chairperson.

 

The Board of Directors resolved to establish an Audit Committee and a Remuneration Committee. The members of the Committees were elected as follows:

  • Audit Committee: Päivi Malinen (Chairperson), Michael Piccirillo and Sarah van Hellenberg Hubar-Fisher
  • Remuneration Committee: Sarah van Hellenberg Hubar-Fish (Chairperson), Antti Vasara and Justin Barad.

 

The Board of Directors assessed the independence of its members in accordance with the Finnish Corporate Governance Code for listed companies. The Board concluded that the members of the Board are independent of Bioretec and its significant shareholders, except for Kustaa Poutiainen, who is assessed to be independent of the company but not of its significant shareholder, Stephen Industries Inc Oy, due to his role as chairperson of the board of Stephen Industries Inc Oy.

 

The Board further resolved, on the basis of the authorization granted by the Annual General Meeting, to establish a new option program (2025-2) and to grant in aggregate 610,105 option rights to Alan Donze, the CEO of the company, entitling to the subscription of a maximum of 610,105 shares in the company. The company will later today publish a separate release providing additional information regarding the option program.

 

Further enquiries

Kustaa Poutiainen, Chairperson of the Board, + 358 40 042 4506

Alan Donze, CEO, telephone + 1 619 977 5285

 

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

by Admin

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)


<br /> ViewReleaseInStandardHtml<br />

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Bioretec Ltd Company announcement 14 March 2025 at 7:30 p.m. EET

Bioretec Ltd has on 14 March 2025 received a notification in accordance with the Securities Market Act, according to which the holdings of shares and votes of W&M GmbH in Bioretec Ltd have on 14 March 2025 crossed the threshold of 5%.

 

Total position of W&M GmbH according to the notification:

 

 

% of shares and voting rights

% of shares and voting rights through financial instruments

Total of both in %

Total number of shares and voting rights of the issuer

Resulting situation on the date on which threshold was crossed or reached

5.78%

0%

5.78%

24,566,474

Position of previous notification (if applicable)

 

 

 

 

 

Notified details of the resulting situation on the date on which the threshold was crossed:

 

 

Number of shares and voting rights

% of shares and voting rights

Class/type of shares
ISIN code

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

Direct (SMA 9:5)

Indirect (SMA 9:6 and 9:7)

FI4000480454

1,419,616

0

5.78%

0%

SUBTOTAL

1,419,616

5.78%

 

After 14 March 2025, W&M GmbH holds 5.78% of the shares and votes.

 

 

Further enquiries

Johanna Salko, CFO, +358 40 754 8172

 

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

 

Bioretec in brief

 

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable USD 9 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment.

 

Better healing – Better life. www.bioretec.com

 

 

 

by Admin